Dennis W. Stacey

Dennis W. Stacey

Auto-generated profile, based on publicly available information

Dennis W. Stacey

Department of Molecular Medicine, Case Western Reserve University, and Department of Molecular Genetics, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2003 in Current Opinion in Cell Biology
Verified
Journal Article
Closed access
DSDennis W Stacey
Dennis W Stacey

18 December 2006 in Cell Division
Verified
Journal Article
Open access
PDF file
KYKe Yang
Ke Yang
MHMasahiro Hitomi
Masahiro Hitomi
DSDennis W Stacey
Dennis W Stacey
We present evidence that variations in cyclin D1 levels through the cell cycle are essential for continuing proliferation. Cyclin D1 levels must be high during G1 phase for a cell to initiate DNA synthesis, but then must be suppressed to low levels during S phase to allow for efficient DNA synthesis. This suppression during S phase is apparently regulated by cell cycle position alone and occurs automatically during each cell cycle. If the cell is to continue proliferating, cyclin D1 levels must be induced once again during G2 phase. This induction depends upon the activity of proliferative signaling molecules, and ensures that the extracellular environment continues to be conducive for growth. We propose that the suppression of cyclin D1 levels during each S phase ensures that the subsequent induction during G2 phase, and the resulting commitment to continuing proliferation, is closely linked to the cellular growth environment.

1 October 1999 in Current Biology
Verified
Journal Article
Closed access
MHMasahiro Hitomi
Masahiro Hitomi
DSDennis W. Stacey
Dennis W. Stacey

21 February 2005 in Oncogene
Verified
Journal Article
Closed access
YGYang Guo
Yang Guo
KYKe Yang
Ke Yang
JHJyoti Harwalkar
Jyoti Harwalkar
JNJeffrey M Nye
Jeffrey M Nye
DMDavid R Mason
David R Mason
DSDennis W Stacey
Dennis W Stacey

1 July 1999 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
MHMasahiro Hitomi
Masahiro Hitomi
DSDennis W. Stacey
Dennis W. Stacey
Novel techniques were used to determine when in the cell cycle of proliferating NIH 3T3 cells cellular Ras and cyclin D1 are required. For comparison, in quiescent cells, all four of the inhibitors of cell cycle progression tested (anti-Ras, anti-cyclin D1, serum removal, and cycloheximide) became ineffective at essentially the same point in G1 phase, approximately 4 h prior to the beginning of DNA synthesis. To extend these studies to cycling cells, a time-lapse approach was used to determine the approximate cell cycle position of individual cells in an asynchronous culture at the time of inhibitor treatment and then to determine the effects of the inhibitor upon recipient cells. With this approach, anti-Ras antibody efficiently inhibited entry into S phase only when introduced into cells prior to the preceding mitosis, several hours before the beginning of S phase. Anti-cyclin D1, on the other hand, was an efficient inhibitor when introduced up until just before the initiation of DNA synthesis. Cycloheximide treatment, like anti-cyclin D1 microinjection, was inhibitory throughout G1 phase (which lasts a total of 4 to 5 h in these cells). Finally, serum removal blocked entry into S phase only during the first hour following mitosis. Kinetic analysis and a novel dual-labeling technique were used to confirm the differences in cell cycle requirements for Ras, cyclin D1, and cycloheximide. These studies demonstrate a fundamental difference in mitogenic signal transduction between quiescent and cycling NIH 3T3 cells and reveal a sequence of signaling events required for cell cycle progression in proliferating NIH 3T3 cells.

30 August 2006 in BMC Cell Biology
Verified
Journal Article
Open access
PDF file
KYKe Yang
Ke Yang
YGYang Guo
Yang Guo
WSWilliam C Stacey
William C Stacey
JHJyoti Harwalkar
Jyoti Harwalkar
JFJonathan Fretthold
Jonathan Fretthold
DSDennis W Stacey
Dennis W Stacey
The expression level of cyclin D1 plays a vital role in the control of proliferation. This protein is reported to be degraded following phosphorylation by glycogen synthase kinase 3 (GSK3) on Thr-286. We recently showed that phosphorylation of Thr-286 is responsible for a decline in cyclin D1 levels during S phase, an event required for efficient DNA synthesis. These studies were undertaken to test the possibility that phosphorylation by GSK3 is responsible for the S phase specific decline in cyclin D1 levels, and that this event is regulated by the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway which controls GSK3. We found, however, that neither PI3K, AKT, GSK3, nor proliferative signaling activity in general is responsible for the S phase decline in cyclin D1 levels. In fact, the activity of these signaling kinases does not vary through the cell cycle of proliferating cells. Moreover, we found that GSK3 activity has little influence over cyclin D1 expression levels during any cell cycle phase. Inhibition of GSK3 activity by siRNA, LiCl, or other chemical inhibitors failed to influence cyclin D1 phosphorylation on Thr-286, even though LiCl efficiently blocked phosphorylation of β-catenin, a known substrate of GSK3. Likewise, the expression of a constitutively active GSK3 mutant protein failed to influence cyclin D1 phosphorylation or total protein expression level. Because we were unable to identify any proliferative signaling molecule or pathway which is regulated through the cell cycle, or which is able to influence cyclin D1 levels, we conclude that the suppression of cyclin D1 levels during S phase is regulated by cell cycle position rather than signaling activity. We propose that this mechanism guarantees the decline in cyclin D1 levels during each S phase; and that in so doing it reduces the likelihood that simple over expression of cyclin D1 can lead to uncontrolled cell growth.